Скачать или смотреть Can HIV Be Cured? A Former St. Jude's Pediatric Oncologist Dr. Ely Benaim Thinks Its Possible At AGT

Learn More About Dr. Ely Benaim, Scientific Advisor of AGT here: https://www.americangene.com/agt_advi...
Learn More About AGT's HIV Cure Program here: https://www.americangene.com/developm...

How does gene therapy work? Definition by National Institutes of Health:
http://ghr.nlm.nih.gov/handbook/thera...
"Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein."

Cell and Gene Therapy for HIV Cure Article Published by National Institutes of Health:
https://www.ncbi.nlm.nih.gov/pubmed/2...
"Cell and gene therapy strategies are connected with human pathologies at a fundamental level, by delivering DNA and RNA molecules that could correct and/or ameliorate the underlying genetic factors of any illness...Today, HIV-based lentiviral vectors, along with many other gene delivery strategies, have been used to evaluate HIV cure approaches in cell culture, small and large animal models, and in patients..."

Video Transcription:

My name is Dr. Ely Benaim. As a Pediatric Oncologist, I trained at St. Jude's Children's Research Hospital, where I worked in the area of transplantation and gene therapy. Once I moved into industry, this knowledge was used in a company called Sangamo Biosciences where we did one of the first trials in HIV patients where we ex vivo, or outside the body, we manipulate the entrance of the virus into the T cells.

HIV is a terrible disease, but fortunately, we have been able to transform a very mortal or lethal disease into a chronic disease. So now people say "Well, why do we need more therapies for HIV? People are living with HIV and taking medications for it". The truth is that it's very onerous on all of these patients to take so much therapy and in spite of the therapy there are still patients that have accelerated aging; that they will die from this disease.

AGT brings a new form of therapy, really trying to push into curing HIV. So any manipulation of cells, with the goal of destroying this T cell and destroying where the virus hides in the body, eventually if they are successful will mean the cure of HIV instead of making the HIV a chronic disease. For me, AGT has become one of these companies that resonates on my personal level of looking for new technologies, new advances and really trying to push the line on therapies for terrible diseases, like HIV.

About Dr. Ely Benaim, Scientific Advisor of AGT:

Ely Benaim, MD has more than 25 years of experience in healthcare including 15 years of clinical research experience in academia, government, and pharmaceutical industry as well as extensive experience in global regulatory affairs. Dr. Benaim was most recently Senior Vice President of Regulatory Affairs & Chief Medical Officer of Berg Pharma. Prior to joining Berg Pharma, Dr. Benaim was Global Clinical Development Leader at Millennium/Takeda Pharmaceuticals where he oversaw global clinical development of the Aurora A kinase inhibitor program. Prior to joining Takeda in 2011, Dr. Benaim served as Vice President of Clinical Affairs for Sangamo BioSciences where he led the development of zinc-fingers transcription factors cellular therapies in the areas of Cancer, Diabetes, Neurology, Cardiovascular and HIV. Before Sangamo, Dr. Benaim served at Amgen as Global Clinical Lead for the development of rilotumumab, a hepatocyte growth factor antibody for solid tumors, currently in late-stage development. Prior to Amgen he was a Senior Director, Oncology Clinical Development at Salmedix/Cephalon Inc. (now Teva, Inc.) where he led the development of TREANDA® to a Phase 3 pivotal trial for lymphoma. Dr. Benaim received his M.D. from the Universidad Central de Venezuela, Caracas and completed his pediatric residency training at the University of South Florida. He completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude’s Children’s Research Hospital, in Memphis, Tennessee. From 1997 to 2004, he was Assistant Professor in the Department of Pediatrics at the University of Tennessee and an Assistant Member to the Department of Hematology/Oncology. As a member of the Transplantation and Gene Therapy program he published several manuscripts on the areas of stem cell transplantation, immunology and gene therapy. Dr. Benaim also has a passion for global pediatric cancer awareness and care and has been awarded for his contributions in Latin America and the United States.

If you liked this video, hit the subscribe button!